disease

(redirected from Hemolytic disease of the newborn)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
Sold in more than 40 countries, WinRho(R)SDF is an antibody to certain types of red blood cell and is currently indicated to prevent hemolytic disease of the newborn, which is a serious blood-type incompatibility between a pregnant woman and the fetus, and to treat ITP, which is an autoimmune condition that impairs blood-clotting ability through a decrease in platelet levels.
Rare cases of hemolytic disease of the newborn in pregnant patients with the weak D phenotype have been reported[16-18] and may be one of the underlying reasons for the relatively high percentage who would administer Rh immune globulin in this clinical setting.
a] was previously described as the cause of hemolytic disease of the newborn from the serum of a Venezuelan female in 1956.
Symphogen and Biovitrum are developing a recombinant, polyclonal antibody for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and anti-RhD prophylaxis of Hemolytic Disease of the Newborn (HDN).
About Sym001 Sym001 consists of 25 different recombinant polyclonal anti-Rhesus D antibodies for the treatment of Idiopathic Thrombocytopenic Purpura and for the prevention of Hemolytic Disease of the Newborn.
Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of the Newborn (HND).

Full browser ?